N/A N=14 Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes
Diabetes Mellitus, Type 1
Primary: Mean Energy Expenditure Between HIIT and MICT — 264.5; 225.5 kcal — p=0.010
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Effect of Opioids on Ventilation in Children With Obstructive Sleep Apnea
Respiratory Depression · Obstructive Sleep Apnea
Primary: Respiratory Depression Following Opioids — -38.1; -37.1 percentage of change from baseline
N/A N=48 The LoBAG Diet and Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in Hemoglobin A1c From Baseline to Week 12 — 6.6; 7.2 percentage
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
N/A N=677 Exceed ABT Acetabular Cup Cementless System
Osteoarthritis · Rheumatoid Arthritis · Correction of Functional Deformity
Primary: Harris Hip Score — 89.8; 90.4 score on a scale
N/A N=50 SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Sarcoidosis · Fatigue
Primary: Proportion of Participants Recruited — 25; 25 Participants
N/A N=10 Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
Oligometastases of the Spine
Primary: Number of Participants to Receive Delivery of the First Fraction of Same-session MRI-only Simulation and Treatment With SMART on the First On-table Attempt — 8…
Phase 1 N=45 Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Hypertrophic Cardiomyopathy
Primary: Area Under the Curve (AUC) (0-last), AUC(0-inf) — 9956; 20040; 18270; 39980 h*ng/mL
N/A N=10 A First in Human Study to Compare Feasibility of Inertial Cavitation Irrigation to SNI in Root Canal Treatment.
Root Canal Treatment · Post Operative Pain
Primary: Clinical Postoperative Pain — 30.5; 20.6 score on a scale
N/A N=128 Storytelling to Increase Family Support for Pre Exposure Prophylaxis Use
HIV Infections
Primary: Adherence to PrEP Medication — 96.6; 95.5 percentage of pills taken daily
Phase 2 N=26 Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Congestive Heart Failure · Heart Failure, Diastolic
Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…
Phase 3 N=193 RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤…
Phase 1 N=53 A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
Schizophrenia
Primary: Number of Participants Experiencing an Adverse Event (AE) — 3; 2; 0; 3 Participants
N/A N=1,057 Preoperative Education
Postoperative Pain
Primary: Opioid Consumption — 23; 26 Morphine milligrams equivalent — p=0.890
Phase 1 N=45 A Safety Study of Mirikizumab (LY3074828)
Psoriasis
Primary: Number of Participants With One or More Adverse Event(s) (AEs) Considered by the Investigator to Be Related to Study Drug Administration — 1; 1; 2; 0 Participants